{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:54:29Z","timestamp":1784202869767,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/maj.0b013e31822b7bb8","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T22:32:10Z","timestamp":1317767530000},"page":"352-355","source":"Crossref","is-referenced-by-count":41,"title":["Neurological Deficits During Treatment With Tumor Necrosis Factor-Alpha Antagonists"],"prefix":"10.1016","volume":"342","author":[{"given":"Kenkichi","family":"Nozaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Stickler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada G.","family":"Abou-Fayssal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane L.","family":"Kamen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/MAJ.0b013e31815d8276","article-title":"Sarcoidosis: clinical presentation, diagnosis, and approach to treatment","volume":"335","author":"Judson","year":"2008","journal-title":"Am J Med Sci"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clim.2007.08.012","article-title":"TNFalpha blockade in human diseases: an overview of efficacy and safety","volume":"126","author":"Lin","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0025","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneurol.2009.11","article-title":"Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy","volume":"66","author":"Lozeron","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0030","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0035","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/03009740802136164","article-title":"Multiple sclerosis following etanercept treatment for ankylosing spondylitis","volume":"37","author":"Pfueller","year":"2008","journal-title":"Scand J Rheumatol"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000109576","article-title":"Multiple sclerosis onset during etanercept treatment","volume":"59","author":"Gomez-Gallego","year":"2008","journal-title":"Eur Neurol"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0050","first-page":"239","article-title":"Adalimumab-associated multiple sclerosis","volume":"34","author":"Bensouda-Grimaldi","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0055","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0060","first-page":"1457","article-title":"Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab","volume":"33","author":"Ruiz-Jimeno","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0065","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s10067-005-0097-x","article-title":"New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients","volume":"25","author":"Tanno","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0070","doi-asserted-by":"crossref","first-page":"234","DOI":"10.20452\/pamw.370","article-title":"Neurological disorders with demyelinating brain white matter lesions in a patient with rheumatoid arthritis treated with etanercept","volume":"118","author":"Kur-Zalewska","year":"2008","journal-title":"Pol Arch Med Wewn"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0075","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3109\/s10165-008-0062-z","article-title":"A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy","volume":"18","author":"Kameda","year":"2008","journal-title":"Mod Rheumatol"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0080","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/art.21814","article-title":"Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy","volume":"54","author":"Shin","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"suppl 1","key":"10.1097\/MAJ.0b013e31822b7bb8_bb0085","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1007\/s10067-009-1154-7","article-title":"Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy","volume":"28","author":"Bouchra","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0090","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/ard.2005.043208","article-title":"Guillain-Barre syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature","volume":"67","author":"Silburn","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0095","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1212\/01.WNL.0000158681.29117.8B","article-title":"Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers","volume":"64","author":"Richez","year":"2005","journal-title":"Neurology"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0100","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10067-009-1174-3","article-title":"A case of spontaneously recovering multifocal motor neuropathy with conduction blocks (MMNCB) during anti-TNF alpha therapy for ankylosing spondylitis","volume":"28","author":"Paolazzi","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0105","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/mus.21051","article-title":"Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis","volume":"38","author":"Hooper","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(03)00010-8","article-title":"Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy","volume":"210","author":"Chin","year":"2003","journal-title":"J Neurol Sci"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0115","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/gut.52.7.1070-a","article-title":"Caution with the use of cyclosporin in pregnancy","volume":"52","author":"Dor","year":"2003","journal-title":"Gut"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0120","first-page":"1018","article-title":"Neurological complications of infliximab","volume":"33","author":"Jarand","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0125","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2010.01.004","article-title":"Acute motor and sensory axonal neuropathy and concomitant encephalopathy during tumor necrosis factor-alpha antagonist therapy","volume":"291","author":"Faivre","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0130","first-page":"2079","article-title":"Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis","volume":"31","author":"Richette","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0135","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/gut.2006.093294","article-title":"Fatal aseptic meningoencephalitis following infliximab treatment for inflammatory bowel disease","volume":"55","author":"Quispel","year":"2006","journal-title":"Gut"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0140","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1086\/605498","article-title":"Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors","volume":"49","author":"Bradford","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0145","first-page":"546","article-title":"Arterial thrombosis with anti-phospholipid antibodies induced by infliximab","volume":"17","author":"Nosbaum","year":"2007","journal-title":"Eur J Dermatol"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0150","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00415-010-5591-7","article-title":"Neurological adverse events associated with anti-tumor necrosis factor alpha treatment","volume":"257","author":"Tristano","year":"2010","journal-title":"J Neurol"},{"key":"10.1097\/MAJ.0b013e31822b7bb8_bb0155","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/mus.20924","article-title":"Tumor necrosis factor-alpha antagonists and neuropathy","volume":"37","author":"Stubgen","year":"2008","journal-title":"Muscle Nerve"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915311290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915311290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:44:55Z","timestamp":1741783495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915311290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0002962915311290"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e31822b7bb8","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}